You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Litigation Details for Nokia Technologies Oy v. ASUSTeK Computer Inc. (C.D. Cal. 2025)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Nokia Technologies Oy v. ASUSTeK Computer Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis for Nokia Technologies Oy v. ASUSTeK Computer Inc. | 2:25-cv-03053

Last updated: February 20, 2026

Case Overview

Nokia Technologies Oy filed a patent infringement complaint against ASUSTeK Computer Inc. in the United States District Court for the Central District of California. The case number is 2:25-cv-03053. The lawsuit concerns alleged infringement of Nokia’s patents related to wireless communication technologies, primarily targeting ASUS’s mobile devices and laptops integrating those technologies.

Timeline and Case Development

  • Filing Date: March 20, 2025. Nokia initiated the suit, alleging infringement of multiple patents related to 4G LTE and 5G NR standards.

  • Patents Involved: The complaint lists nine patents, primarily focusing on aspects of cellular connectivity, antenna design, and data transmission algorithms.

  • Defendant Response: ASUS filed an answer on May 15, 2025, denying infringement and asserting non-infringement and invalidity of the patents.

  • Discovery Phase: Began June 1, 2025, with document exchanges and technical depositions. Nokia seeks information about ASUS device architecture, source code, and chipset specifications.

  • Motions: Both parties filed preliminary motions. Nokia moved for a preliminary injunction to halt sales of infringing products, while ASUS sought to dismiss specific patent claims, claiming prior art and obviousness.

  • Current Status (as of October 2025): The court has scheduled a Markman hearing for December 2025 to interpret patent claim language, with a trial date set for August 2026.

Patent Features and Alleged Infringements

  • Patent Scope: The patents concern efficient data transfer in cellular networks, with innovations in antenna array configurations and signal processing for enhanced throughput.

  • Infringing Products: The complaint identifies ASUS ZenFone series and certain ROG laptops as infringing products. These devices use Qualcomm Snapdragon modems supporting 4G LTE and 5G NR.

  • Technological Impact: Nokia argues that ASUS’s implementation infrings on patented core functionalities, such as MIMO antenna configurations and dynamic beamforming algorithms.

Legal and Technical Challenges

  • Invalidity Claims: ASUS contests patent validity based on prior art references, including earlier wireless standards and commercial implementations predating Nokia's patents.

  • Claim Construction: The upcoming Markman hearing aims to clarify disputed patent terms, a critical step influencing infringement and validity arguments.

  • Market Impact: If Nokia successfully proves infringement, remedies could include injunctions and monetary damages, potentially affecting ASUS’s product line.

Strategic Considerations

  • Patent Licensing: Nokia may pursue licensing agreements if infringement is established, particularly given the popularity of ASUS devices in the global market.

  • Trade Secret Aspects: Nokia claims its patents encompass proprietary technologies critical to next-generation wireless standards, complicating invalidity defenses.

  • Cross-Licensing: Given the industry’s complex patent landscape, ASUS might explore cross-licensing to mitigate risks or settle.

Comparative Context

Aspect Nokia Technologies Oy ASUS Industry Standard Practices
Patent Portfolio Focused on wireless standards Devices implementing industry standards Industry often involves patent pools or cross-licenses
Litigation Strategy Assert core patents to protect standards Challenge validity and seek licenses Litigation used to negotiate licensing terms
Market Impact High due to wireless dominance Significant due to broad device portfolio Litigation from patent holders influences device design

Key Takeaways

  • The lawsuit centers on wireless technology patents critical to modern mobile communications.
  • Nokia aims to enjoin ASUS from manufacturing and selling infringing products.
  • The case hinges on claim interpretation and patent validity challenges.
  • A resolution may involve infringement findings, invalidity rulings, or licensing agreements.
  • The outcome could influence licensing practices and competitive positioning in wireless markets.

FAQs

1. What patents does Nokia claim ASUS infringes?
Nokia alleges infringement of nine patents related to wireless data transfer, antenna design, and signal processing, mainly pertaining to LTE and 5G technologies.

2. What is the significance of the Markman hearing?
It sets the interpretation of patent claim language, which directly affects the infringement analysis and potential validity defenses.

3. Could ASUS challenge Nokia's patents as invalid?
Yes, ASUS has indicated it will argue prior art references and obviousness to invalidate the patents.

4. What remedies could Nokia seek if infringement is proven?
Injunctions to stop product sales and monetary damages for past infringement.

5. How does this case compare to industry norms?
It reflects common practices of patent enforcement in the wireless industry, including assertions of essential patents and strategic litigation.


References

  1. U.S. District Court for the Central District of California. (2025). Case No. 2:25-cv-03053.
  2. Nokia Technologies Oy. (2025). Complaint against ASUS.
  3. ASUS. (2025). Answer and defenses to the complaint.
  4. Wireless Standard Patent Practices. (2021). Industry Patent Strategies Report.
  5. Patent Litigation Trends in Wireless Technology. (2023). Bloomberg Intelligence.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.